TY - JOUR T1 - Montelukast moderately decreased asthma symptoms in children with persistent asthma JF - Evidence Based Medicine JO - Evid Based Med SP - 77 LP - 77 DO - 10.1136/ebm.7.3.77 VL - 7 IS - 3 A2 - , Y1 - 2002/05/01 UR - http://ebm.bmj.com/content/7/3/77.abstract N2 - (2001) Pediatrics 108, e48. Knorr B, Franchi LM, Bisgaard H, et al. . Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.. Sep;. :. ..OpenUrlAbstract/FREE Full Text 
 
 QUESTION: In children with persistent asthma, is montelukast a well tolerated and effective therapeutic option? Randomised {allocation concealed*}†, blinded (patients, clinicians, and {data collectors}†),* placebo controlled trial with 12 weeks of follow up. 93 centres in Africa, Australia, Europe, North America, and South America. 689 children who were 2 to 5 years of age (mean age 4 y, 59% boys, 56% white), had ≥ 3 episodes of asthma symptoms in the previous year, had a total asthma symptom score ≥ 1 (of 24) for ≥ 8 days during the 2 week placebo baseline period, and used β agonists for ≥ 8 days during the placebo baseline period. Exclusion criteria included asthma intubation and emergency department treatment or admission … ER -